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Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1
receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness
and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use
of PD-L1 testing for patient selection.
Design: We developed a decision-analytic model to determine the cost-effectiveness of PD-L1 assessment and second-line
immunotherapy versus docetaxel. The model used outcomes data from randomized clinical trials (RCTs) and drug acquisition
costs from the United States. Thereafter, we used epidemiologic data to estimate the economic impact of the treatment.
Results: We included four RCTs (2 with nivolumab, 1 with pembrolizumab, and 1 with atezolizumab). The incremental quality-
adjusted life year (QALY) for nivolumab was 0.417 among squamous tumors and 0.287 among non-squamous tumors and the
incremental cost-effectiveness ratio (ICER) were $155 605 and $187 685, respectively. The QALY gain in the base case for
atezolizumab was 0.354 and the ICER was $215 802. Compared with treating all patients, the selection of patients by PD-L1
expression improved incremental QALY by up to 183% and decreased the ICER by up to 65%. Pembrolizumab was studied only
in patients whose tumors expressed PD-L1. The QALY gain was 0.346 and the ICER was $98 421. Patient selection also reduced
the budget impact of immunotherapy.
Conclusion: The use of PD-L1 expression as a biomarker increases cost-effectiveness of immunotherapy but also diminishes
the number of potential life-years saved.
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Introduction
Lung cancer is the most common cause of cancer-related death in
the United States and the world [1, 2]. The incidence and mortal-
ity rate of lung cancer in the United States is 57.3 and 46.0 per
100 000, respectively, with 224 390 projected new cases and
158 050 deaths in 2016 [2, 3].
Despite innovative drug development in the past two decades,
there are few options for second-line treatment and the most
commonly used agent in the United States before the advent of
immune checkpoint inhibitors was docetaxel [4].
Evasion of the immune system is a primary feature of cancers
[5]. One mechanism by which tumor cells (TC) can evade im-
mune surveillance checkpoints is by triggering apoptosis of
T-lymphocytes by binding to Programmed Death-1 (PD-1) re-
ceptors [6, 7]. Advancements in our understanding of this mech-
anism has led to the rational design of three FDA-approved
monoclonal antibodies that specifically target and block the PD-
L1/PD-1 interaction: nivolumab, pembrolizumab, and atezolizu-
mab [8–11].
As such PD-L1 expression is presumably a logical predictor of
outcomes for patients treated with immune checkpoint inhibitors.
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Two recentmeta-analyses have shown response and survival to im-
munotherapy to increase proportionally with the extent of PD-L1
expression in TC [12, 13]. A targeted approach to treatment using
predictive biomarkers has the potential not only to maximize clin-
ical benefit, but also to improve cost-effectiveness and reduce the
economic burden of the disease.
As the global impact of non-small-cell lung cancer (NSCLC)
continues to grow, the implementation of novel and more effect-
ive therapies becomes important but also costly [14]. Analysis of
the cost-effectiveness and economic impact of new therapies is
imperative to ensure the appropriate and sustainable use of
advanced targeted treatments in NSCLC. The current study in-
vestigates the cost-effectiveness and economic burden of treat-
ment with checkpoint inhibitors with and without patient
selection using PD-L1 expression.
Methods
The authors developed a decision-analytic model using clinical data from
the four available phase III studies (CheckMate 017, CheckMate 057,
KeyNote 010, and OAK Study) [8–11]. The model compared three main
strategies: (i) tumor sample not tested for PD-L1 expression and all pa-
tients treated with docetaxel, (ii) tumor sample not tested for PD-L1 ex-
pression and all patients treated with immunotherapy, and (iii) patients
treated according to their PD-L1 status: immunotherapy for patients
with PD-L1 expression of 1% or more and docetaxel for patients without
PD-L1 expression (Figure 1).
We analyzed data from the perspective of the US Medicare system. We
considered the costs of PD-L1 testing (Dako 22C3 immunohistochemistry
assay), drug acquisition, adverse events, as well as agents prescribed after
progression. Other direct costs such as administration costs, monitoring
costs, and end-of-life costs were also considered [15]. Drug acquisition pri-
ces were based on the USA data. For nivolumab, we considered USD 24.69/
mg on 10 February 2016. For pembrolizumab, we considered USD 43.80/
mg on 10 February 2016. For atezolizumab, we considered USD 10.42/mg
on 14November 2016. The utility of each health state aswell as the disutility
of each relevant adverse event were obtained from the literature [16, 17].
The primary end point of this study was the incremental cost-
effectiveness ratio (ICER) expressed as cost per quality-adjusted life year
(QALY) gained by using immunotherapy compared with docetaxel for
the second-line treatment of NSCLC with or without PD-L1 expression
determining treatment selection.
Secondary end points were the economic impact of each strategy ex-
pressed by the total amount expended each year, the number of life years
saved, and the cost of each life year saved with or without PD-L1 assess-
ment. Deterministic sensitivity analyses were carried out to test the ro-
bustness of the results.
Model structure
In the decision-analytic model (Figure 1), patients were classified into
three mutually exclusive health states: progression-free disease, post-pro-
gression disease, and death.
The PD-L1 positive arm of the model considered 1%, 5%, and 10%
thresholds for nivolumab and 1% and 50% thresholds for
pembrolizumab based on the data available.
For atezolizumab, we considered as positive all patients with PD-L1
expression score above 1 among TC or infiltrating cells (IC). We also div-
ided the patients whose scores were 3 for TC or IC.
Clinical effectiveness and quality of life
We obtained effectiveness data from the area under curves of
progression-free survival (PFS) and overall survival (OS) outcomes
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Figure 1. Decision-analytic model used in the study
Table 1. Deterministic sensitivity analysis parameters
Parameter Mean
deterministic
Lower
value
Upper
value
General
Discount rate 10% NA NA
20% NA NA
Average body weight 70 58.4 87.6
Body Surface Area 1.8 1.46 2.18
Costs
Administration costs (per cycle) $290 $232 $348
Monitoring costs CT (per cycle) $658 $526 $790
Monitoring costs ICI (per cycle) $732 $589 $878
End-of-life costs (per case) $8632 $6906 $10 358
Outcomes
Progression-free survival utility 0.65 0.63 0.67
Post-progression survival utility 0.43 0.39 0.47
Survival
HR on PFS (CM 017) 0.62 0.47 0.81
HR on OS (CM 017) 0.59 0.44 0.79
HR on PFS (CM 057) 0.92 0.77 1.11
HR on OS (CM 057) 0.73 0.59 0.89
HR on PFS (KN 010) 0.88 0.74 1.05
HR on OS (KN 010) 0.71 0.58 0.88
HR on PFS (OAK) 0.95 0.82 1.10
HR on OS (OAK) 0.73 0.62 0.87
CT, chemotherapy; ICI, immune checkpoint inhibitors; HR, hazard ratio;
PFS, progression-free survival; OS, overall survival.
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reported in the trials’ publications and supplementary materials. A
lifetime model was carried out after the updates of the included studies
[18–21]. We considered a horizon of 5 years.
QALY for the time of progression-free disease and the time after pro-
gression were calculated according to published utilities [16, 17]. We
were unable to use different scores for each treatment arm because of the
paucity of published data regarding quality of life. The disutility of the
most frequent adverse events was also considered.
Medical costs
We considered a body weight of 70 kilograms and a body surface area of
1.8 square meters to calculate the costs of each treatment. The costs of ad-
verse events were calculated according to published data corrected by in-
flation [22–24].
The costs of post-progression therapies were calculated according to
the number of patients receiving each post-progression drug listed in the
supplementary material of each study.
Deterministic sensitivity analysis
We carried out several one-way deterministic sensitivity analyses
(DSA) to evaluate the influence of uncertainty in individual input
parameters on the ICER. We considered the 95% confidence intervals
or plausible ranges (if no confidence intervals were available) of uncer-
tainty for the most important variables (Table 1). The probability of
reaching cost-effectiveness based on a Willingness To Pay (WTP)
threshold of USD 100 000 per QALY gained was analyzed with or with-
out PD-L1 testing for each drug assessed by each randomized clinical
trial (RCT).
Budget impact analysis
The number of eligible patients for each treatment strategy was approxi-
mated using the estimated number of new cases in the United States pub-
lished by the Surveillance, Epidemiology, and End Results Program
(SEER) [2]. The proportion of patients in advanced stage treated at the
first- and the second-line setting were calculated using the National Lung
Cancer Audit Report 2014 (NLCA) and the European real life study pub-
lished by Moro-Sibilot et al. respectively [25, 26]. The proportion of pa-
tients with PD-L1 expression1% or50% was retrieved from the
included RCTs [8–10].
The authors considered a hypothetical market penetration of 100%
among each eligible population after the release of immune checkpoints
inhibitors for better understanding of the economic impact of each treat-
ment strategy.
Table 2. Summary of base-case analysis
Parameter Squamous tumors Non-squamous tumors All histology All histology
PD-L1 unselected PD-L1 unselected PD-L1 1% PD-L1 unselected
Nivo Doc Nivo Doc Pembro Doc Atezo Doc
Median No. of cycles 15 5 14 7 9 7 8 7
Drug cost $77 774 $12 326 $72 589 $17 256 $55 188 $17 256 $100 032 $17 256
AEs costs $202 $6922 $1738 $7002 $1380 $3513 $749 $4415
PPS costs $6638 $5925 $6989 $7676 $9599 $12 457 $5947 $9270
EOL costs $7251 $8287 $7251 $8287 $6776 $8261 $7251 $8287
Adm costs $4350 $1450 $4060 $2030 $2610 $2030 $2320 $2030
Mon costs $8238 $3290 $8164 $4606 $6588 $4606 $5856 $4606
Total costs $104 453 $39 516 $100 791 $46 856 $82 201 $48 182 $122 155 $45 864
Mean PFS 7.28 4.07 6.72 5.33 6.56 5.06 6.03 5.25
Mean PPS 11.80 6.45 14.50 9.60 15.78 8.95 16.05 7.95
Mean OS 19.08 10.52 21.22 14.93 22.34 14.01 22.08 13.20
Utility 0.82 0.45 0.88 0.63 0.92 0.59 0.90 0.57
AEs 0.00 0.05 0.01 0.05 0.00 0.02 0.00 0.03
QALY 0.82 0.40 0.87 0.59 0.92 0.57 0.90 0.54
QALY gain 0.417 0.287 0.346 0.354
ICER $155 605 $187 685 $98 421 $215 802
LYG 1.59 0.88 1.77 1.24 1.86 1.17 1.84 1.10
Incremental LYG 0.71 0.53 0.69 0.74
Cost per Incremental LYG $91 034 $102 896 $49 007 $103 095
PD-L1 1% or TC 1 QALY 0.322 QALY 0.480 QALY Above QALY 0.405
ICER by QALY $201 461 ICER by QALY $112 311 ICER by QALY Above ICER by QALY $188 632
PD-L1 5% QALY 0.481 QALY 0.740 QALY NA QALY NA
ICER by QALY $135 080 ICER by QALY $72 897 ICER by QALY NA ICER by QALY NA
PD-L1 10% QALY 0.495 QALY 0.683 QALY NA QALY NA
ICER by QALY $131 159 ICER by QALY $78 921 ICER by QALY NA ICER by QALY NA
PD-L1 50% or TC 3 QALY NA QALY NA QALY 0.409 QALY 0.999
ICER by QALY NA ICER by QALY NA ICER by QALY $80 735 ICER by QALY $76 459
Nivo, nivolumab; Doc, docetaxel; Pembro, pembrolizumab; Atezo, atezolizumab; No, number; AEs, adverse events; PPS, post-progression survival; EOL, end-
of-life; Adm, administering; Mon, monitoring; PFS, progression-free survival; OS, overall survival; TC, tumor cells or infiltrating cells PD-L1 expression score.
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Results
Base-case scenarios
In the base case of patients with squamous histology, the QALY
gained with nivolumab was 0.417, and the corresponding ICER
was USD 155 605. The incremental life-years gain (LYG) was 0.71
and the cost per incremental LYG was USD 91 034. PD-L1 ex-
pression improved incremental QALY only for patients with PD-
L15% and10%, by 15% and 18%, respectively. In the base
case of patients with non-squamous tumors, the incremental
QALY for nivolumab was 0.287, and the corresponding ICER was
USD 187 685. The incremental LYG was 0.53 and the cost per in-
cremental LYG was USD 102 896. PD-L1 expression improved
incremental QALY for patients with PD-L11%, 5%, and
10%, by 67%, 157%, and 137%, respectively.
All patients treated with pembrolizumab had at least 1%
PD-L1 expression. In patients treated with pembrolizumab, the
incremental QALY was 0.346, and the ICER was USD 98 421. The
incremental LYG was 0.69 and the cost per incremental LYG was
USD 49 007. PD-L1 expression above 50% improved QALY by
18% and decreased ICER to USD 80 735.
In the base case of patients treated with atezolizumab, the
QALY gain was 0.354, and the corresponding ICER was USD
215 802. The incremental LYG was 0.74 and the cost per incre-
mental LYG was USD 103 095. PD-L1 expression TC or IC1,
and TC or IC 3 improved incremental QALY by 15% and 183%,
respectively. Table 2 summarizes all base-case results.
Deterministic sensitivity analysis
OS 95% confidence intervals (95% CI) had the strongest influ-
ence on the incremental QALY (ranging from 0.047 in the lower
OS value to 1.202 in the higher OS value). The strongest influence
on incremental costs was body weight [ranging from USD 68 171
for the 95% CI lower body weight (58.4 kg) to USD 250 953 for
the 95%CI higher body weight value (87.6 kg)].
The second most important factor influencing the cost-
effectiveness of immunotherapy were hypothetical discounts in
the immune checkpoint inhibitors acquisition costs. With at least
a 10% discount, the probability that immunotherapy was cost-
effective increased from 21.9% (with no discount) to 23.1% (with
10% of discount), and to 24.3% when a discount of 20% was
considered.
All deterministic sensitivity analysis are summarized in
Tornado Diagrams for eachmonoclonal antibody (Figures 2–5).
Giving immunotherapy only for patients with PD-L1 expres-
sion 1% or TC 1 improved almost all incremental QALY and
ICER ICER lower CI ICER higher CI
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Figure 2. Tornado Diagram for nivolumab vs docetaxel (SQ Tumors). SQ, squamous; PFS, progression-free survival; OS, overall survival;
BSA, body surface area; PPS, post-progression survival; Adm, administration costs; Nivo, nivolumab; Doc, docetaxel; Mon, monitoring
costs; EOL, end-of-life costs;>1%, PD-L1 expression>1%; ICER, incremental cost-effectiveness ratio; CI, confidence interval; WTP, willingness
to pay.
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improved cost-effectiveness as a whole. Considering a WTP of
USD 100 000, PD-L1 expression1% or TC1 increased the
probability that immunotherapy bemore cost-effective than doce-
taxel (from 0% with no testing to 29% with PD-L1 testing; Figure
6A and B).
Budget impact
The estimated number of advanced NSCLC patients eligible for
second-line treatment according to the eligibility criteria previ-
ously used in the RCTs was 37 638, comprised of 8656 patients
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Figure 4. Tornado Diagram for pembrolizumab vs docetaxel. PFS, progression-free survival; OS, overall survival; BSA, body surface area;
PPS, post-progression survival; Adm, administration costs; Pemb, pembrolizumab; Doc, docetaxel; Mon, monitoring costs; EOL, end-of-life
costs;>1%: PD-L1 expression>1%; ICER, incremental cost-effectiveness ratio; CI, confidence interval; WTP, willingness to pay.
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Figure 3. Tornado Diagram for nivolumab vs docetaxel (nSQ Tumors). nSQ, non-squamous; PFS, progression-free survival; OS, overall survival;
BSA, body surface area; PPS, post-progression survival; Adm, administration costs; Nivo, nivolumab; Doc, docetaxel; Mon, monitoring costs;
EOL, end-of-life costs;>1%: PD-L1 expression>1%; ICER, incremental cost-effectiveness ratio; CI, confidence interval; WTP, willingness to pay.
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with squamous histology and 28 982 patients with non-
squamous histology each year.
Treating this entire cohort with nivolumab could lead to an in-
cremental cost of USD 1.6 billion annually. Treating this same co-
hort with atezolizumab could lead to an incremental cost of USD
2.4 billion annually.
Treating only patients with at least 1% PD-L1 expression (46%
of eligible patients) with nivolumab would represent an annual
incremental cost of USD 849million.
Pembrolizumab treatment was studied (in a phase III trial) only
for patients with at least 1% of PD-L1 expression (about two thirds
of patients enrolled to participate in KeyNote 010). The annual in-
cremental cost of this treatment selection strategy would be USD
971 million. Treating only patients with tumor PD-L1 expression
>50% with pembrolizumab (28% of the eligible population)
represents an annual incremental cost of USD 411million.
Discussion
Recently published and presented clinical trials continue to con-
firm the effectiveness of immune checkpoint inhibitors as se-
cond line agents for NSCLC [8–11]. Despite promising results, a
minority of patients with NSCLC respond to these immuno-
therapy agents, underscoring the need for predictive biomarkers
[27]. PD-L1 expression in TCs is such a potential biomarker.
Evidence demonstrates that outcomes are better for patients
whose tumors have increasing levels of PD-L1 [12, 13, 28].
Improving cost-effectiveness through patient selection may in-
crease uptake of immune checkpoint inhibitors by rationalizing
therapy from a clinical standpoint thus making treatment more
cost-effective.
In December 2015, the British National Institute for Health
and Care Excellence (NICE) issued an opinion that nivolumab
was not cost-effective for the second-line treatment of squamous
NSCLC [8]. Without biomarker selection, they estimated ICERs
between GBP 109 000 and GBP 129 000 (USD 133 895 and USD
154 463) when the limit accepted by the institute is generally
around GBP 30 000 (USD 36 852) [29].
Our study found that in most scenarios that did not select pa-
tients by PD-L1 expression immunotherapy is not cost-effective
in the second-line treatment of NSCLC in the United States. PD-
L1 testing may improve cost-effectiveness of immune checkpoint
inhibitors. The deterministic sensitivity analysis confirmed that
these results are robust.
Although nivolumab and atezolizumab are currently approved
for patients with NSCLC who progressed after platinum-doublet
chemotherapy regardless of PD-L1 expression, from the payers’
point of view, treating only patients whose tumors express PD-L1
could decrease the budget impact by up to 50% and this may im-
prove access to these innovative therapies to patients who benefit
the most in resource-constrained settings.
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Figure 5. Tornado Diagram for atezolizumab vs docetaxel. TC, tumor cells or infiltrating cells PD-L1 expression score; PFS, progression-free
survival; OS, overall survival; BSA, body surface area; PPS, post-progression survival; Adm, administration costs; Atezo, atezolizumab; Doc, doce-
taxel; Mon, monitoring costs; EOL, end-of-life costs; ICER, incremental cost-effectiveness ratio; CI, confidence interval; WTP, willingness to pay.
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Our data are comparable to other previously published health
economics analysis [30–32], but other studies were limited by the
inclusion of only one clinical trial comparing nivolumab or pem-
brolizumab versus docetaxel while ours included all published
trials on immune checkpoint inhibitors, placing no restriction on
tumor histology [30–32].
Interestingly, analyzing the nivolumab data, the selection of
patients by PD-L1 expression1% may have a negative impact
in the cost-effectiveness among patients with tumors of squa-
mous histology. That notwithstanding, using a higher PD-L1 ex-
pression cutoff (5% or10%) may improve cost-effectiveness.
This analysis by tumor histology was not possible with pembroli-
zumab nor atezolizumab given the lack of available published
data.
Nonetheless, our model has limitations. Utilities were extrapo-
lated from literature and were not related to the treatments of
the studies included in the analysis, introducing a further possi-
bility of bias [33]. Another limitation is the difficulty in finding
clear data regarding post-progression therapies in the published
RCTs.
Finally, our study was not planned to make comparisons be-
tween immune checkpoint inhibitors. We designed this study to
assess the cost-effectiveness of immunotherapy versus docetaxel
with or without patient selection by PD-L1 expression.
Although we demonstrated that therapy selection based on
PD-L1 expression increases cost-effectiveness and decreases the
overall economic impact of therapy with immune checkpoint in-
hibitors, our results also show that the total number of life-years
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Figure 6. Probability of being cost-effective. 6A: PD-L1 unselected; 6B: PD-L1 positive (PD-L1 1% or Tumor Cells or Infiltrating Cells PD-L1
expression score  1).
Original article Annals of Oncology
2262 | Aguiar et al. Volume 28 | Issue 9 | 2017
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/28/9/2256/3868409 by B-O
n C
onsortium
 Portugal user on 25 July 2019
saved by these drugs would decrease with biomarker selection.
Further clinical, translational and health economics studies and
societal discussion is warranted in order to find the optimal ac-
ceptable strategy for patient selection.
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